Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

PHASE4CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Herpes Simplex Type II
Interventions
DRUG

TDF

Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.

DRUG

Placebo Vaginal Gel

"Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints."

DRUG

Vaginal TFV Gel

Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.

DRUG

Placebo Tablets

TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.

Trial Locations (1)

98104

University of Washington Virology Research Clinic, Seattle

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CONRAD

OTHER

collaborator

Gilead Sciences

INDUSTRY

lead

University of Washington

OTHER